שם החברה: Intellect Neurosciences (Israel) Ltd.

שנת ייסוד: 2005

מספר עובדים:

סקטור: Life sciences

תת סקטור: Biotechnology

פרופיל חברה

We are a development-stage biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and other devastating disorders for which no disease-modifying treatments exist. Our pioneering approach using ANTISENILIN® monoclonal antibodies to reduce beta amyloid toxicity in the brain of Alzheimer's disease has gained considerable momentum over the past few years and leading experts in the field have expressed optimism that drugs being developed using the company's proprietary patented technology herald an exciting new era of drug development for safe and efficacious disease modifying treatments for Alzheimer's disease.